Aktive Positionen von John Pribis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Gründer | - | - |
| Corporate Officer/Principal | - | - |
Karriereverlauf von John Pribis
Ehemalige bekannte Positionen von John Pribis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private-Equity-Analyst | 01.12.2019 | - |
Ausbildung von John Pribis
| Baylor College of Medicine | Graduate Degree |
| Drexel University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Private Equity Analyst | 1 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |
- Börse
- Insiders
- John Pribis
- Erfahrung
